RecruitingSolid Tumors

A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

Eligible age

18+ yrs

Accepts

All genders

Locations

29 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).

Sponsor: Incyte Corporation

You may qualify if…

✓ Histologically or cytologically confirmed metastatic PDAC with a KRAS G12D mutation
✓ No prior systemic treatment in the metastatic setting
✓ ECOG Performance status 0-1
✓ Adequate organ function

You may not qualify if…

✕ Prior treatment with any KRAS inhibitor
✕ Chronic or current active infection requiring systemic treatment within 1 week prior to the first dose of study drug
✕ Known active CNS metastases
✕ Other protocol-defined Inclusion/Exclusion Criteria may apply.